1 Min Read
June 14 (Reuters) - Mallinckrodt Plc
* Mallinckrodt enrolls first patient in Phase 2B trial of H.P. Acthar® gel (repository corticotropin injection) for amyotrophic lateral sclerosis (ALS) Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.